Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for cancer. Unlike autologous approaches that use a patient’s own cells, its candidates are designed as “off-the-shelf” products manufactured from healthy donor cells. The pipeline targets hematologic malignancies and other oncology indications through partnered and proprietary programs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -59.7 | — |
| Q2 2025 | 0 | — | -50.9 | — |
| Q3 2025 | 0 | — | -41.4 | — |
| Q4 2025 | 0 | — | -38.8 | — |
| Q1 2026 | 0 | — | -42.6 | — |
| Q2 2026 | 4.6 | — | -42.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Consolidated Water Co. Ltd. (CWCO), Tilray Brands, Inc. (TLRY), Oculis Holding AG (OCS), Gores Holdings XI, Inc. (GHXI), Kamada Ltd. (KMDA), NRC Health (NRC)